73907-95-6

Usage

Uses

Used in Pharmaceutical Industry:
6-Amino-1H-indazole-7-carboxylic acid is used as a key intermediate for the synthesis of various pharmaceutical compounds, contributing to the development of new drugs with potential therapeutic applications. Its unique structure and properties make it a valuable component in the creation of medications that can address a wide range of health concerns.
Used in Research and Development:
6-Amino-1H-indazole-7-carboxylic acid is employed as a research compound in the field of medicinal chemistry, allowing scientists to explore its potential interactions with biological targets and understand its role in drug discovery. 6-Amino-1H-indazole-7-carboxylic acid serves as a foundation for designing and optimizing new molecules with improved pharmacological properties and therapeutic efficacy.
Used in Drug Synthesis:
6-Amino-1H-indazole-7-carboxylic acid is utilized as a building block in the synthesis of complex drug molecules, enabling the creation of innovative pharmaceuticals with enhanced efficacy and reduced side effects. Its presence in the molecular structure of these drugs can influence their pharmacokinetics, pharmacodynamics, and overall therapeutic performance.
Used in Quality Control and Testing:
6-Amino-1H-indazole-7-carboxylic acid is used as a reference compound in the quality control and testing processes of pharmaceutical manufacturing, ensuring the consistency, purity, and potency of the final drug products. Its presence in these processes helps maintain the high standards required for the safety and effectiveness of medications.

Upstream product

• 6967-12-0 6-amino-1H-indazole 
• 73907-93-4 2-[(E)-Hydroxyimino]-N-(1H-indazol-6-yl)-acetamide 
• 73907-93-4 6-(isonitrosoacetamido)indazole 
• 77929-34-1 6-(hydroximinoacetyl)-amino-1H-indazole hydrochloride 
• 73907-94-5 pyrrolo<2,3-g>indazole-7,8-dione 

Downstream Products

• 75844-39-2 6-amino-7-methoxycarbonyl-1-methylindazol 
• 73907-98-9 6-amino-1H-indazole-7-carboxylic acid methyl ester 
• 154597-37-2 6-amino-7-indazolecarboxaldehyde 
• 73907-90-1 prox-benzoisoallopurinol 
• 73907-96-7 6-(β-benzoylthioureido)indazole-7-carboxylic acid 
• 73907-99-0 ethyl 6-aminoindazole-7-carboxylate 

Relevant academic research and scientific papers

PESTICIDES CONTAINING A BICYCLIC BISAMIDE STRUCTURE

Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.

SYNTHESIS OF A -LINKED PYRAZOLOQUINAZOLINONE

A convenient synthesis is described for pyrazoloquinazolin-9-one (4), an internally expanded benzolog of the biologically relevant pyrazolopyrimidines (2).

Synthesis of prox-Benzoisoallopurinol

Pyrazoloquinazolin-9-one (prox-benzoisoallopurinol, 1), an extented analogue of 7-hydroxypyrazolopyrimidine (isoallopurinol, 2) and a potential dimensional probe for substrates of xanthine oxidase, has been synthesized by two independent routes.The title compound, prepared by elaboration of either a suitably substituted indazole or a quinazolinone, was found to be an active substrate for and an alternative-substrate inhibitor of xanthine oxidase.The product of enzymatic oxidation of prox-benzoisoallopurinol has been identified as the corresponding prox-benzoisoalloxanthine.

Quinazoline derivatives

Novel quinazoline derivatives of the formula (1) STR1 wherein ring C is a pyrazole ring fused to ring B in two vicinal positions thereof that are not fused with ring A. The novel formula (1) compounds or pyrazolo-quinazoline-ones are structurally related to allopurinol, a well known drug useful in the treatment of gout and are expected to replace or complement allopurinol in the therapeutic use thereof. The generic name Benzoallopurinol is suggested for the novel formula (1) compounds; formula (1) includes angular and linear structures of the interfused rings A, B and C. Two methods for producing the novel formula (1) compounds are disclosed. The first method starts from the indazole structure that includes the interfused rings B and C, and ring A is formed on the indazole moiety. The second method starts from the quinazoline structure that includes interfused rings A and B, and the pyrazole ring C is formed on the benzo moiety (ring B) of the quinazoline structure. Either method may lead to angular or linear benzoallopurinols depending upon the substituents introduced into the starting structure for forming the complemental ring thereon.